全文获取类型
收费全文 | 314篇 |
免费 | 20篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 7篇 |
妇产科学 | 6篇 |
基础医学 | 40篇 |
口腔科学 | 13篇 |
临床医学 | 37篇 |
内科学 | 76篇 |
皮肤病学 | 11篇 |
神经病学 | 35篇 |
特种医学 | 14篇 |
外科学 | 38篇 |
综合类 | 11篇 |
预防医学 | 22篇 |
眼科学 | 1篇 |
药学 | 10篇 |
中国医学 | 1篇 |
肿瘤学 | 19篇 |
出版年
2023年 | 2篇 |
2022年 | 4篇 |
2021年 | 7篇 |
2020年 | 6篇 |
2019年 | 8篇 |
2018年 | 13篇 |
2017年 | 11篇 |
2016年 | 8篇 |
2015年 | 11篇 |
2014年 | 14篇 |
2013年 | 11篇 |
2012年 | 23篇 |
2011年 | 22篇 |
2010年 | 12篇 |
2009年 | 10篇 |
2008年 | 15篇 |
2007年 | 31篇 |
2006年 | 19篇 |
2005年 | 13篇 |
2004年 | 14篇 |
2003年 | 11篇 |
2002年 | 14篇 |
2001年 | 3篇 |
2000年 | 7篇 |
1999年 | 3篇 |
1998年 | 9篇 |
1997年 | 8篇 |
1996年 | 2篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 5篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1980年 | 2篇 |
1977年 | 2篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有341条查询结果,搜索用时 31 毫秒
1.
2.
3.
目的 真核表达人呼吸道合胞病毒(human respiratory syncytial virus,SV)融合蛋白(fusion protein,),并完成蛋白纯化及纯度测定.方法 根据编码F蛋白的基因序列设计引物,CR方法扩增出3'端带His标签的F基因序列,克隆入pGEM-T-easy载体,经核酸序列分析后,进一步克隆到pcDNA3.1( )真核表达载体,限制性内切酶鉴定,用脂质体Lipofectamine2000转染COS-7细胞,2 h后再用Westem blot检测目的蛋白的表达.Ni柱亲和层析纯化COS-7细胞表达的F蛋白,高效毛细管电泳分析纯化后蛋白纯度.结果 核酸序列分析证实获得带His标签的RSV F基因序列,没有发生无义突变.转染COS-7细胞后,利用Western blot方法检测到F蛋白的特异性条带,纯度达99%以上.结论 初步建立了真核表达RSV F蛋白的纯化方法,为进一步优化RSV F蛋白制备条件及单克隆抗体及诊断试剂等研究奠定了基础. 相似文献
4.
5.
Andrea Bonetti Marta Zaninelli Stefania Rodella Annamaria Molino Loris Sperotto Quirino Piubello Franco Bonetti Rolando Nortilli Monica Turazza Gian Luigi Cetto 《Breast cancer research and treatment》1996,38(3):289-297
Summary The relationship between tumor proliferative activity and response to first-line chemotherapy and survival was investigated in 76 advanced breast cancer patients. Proliferative activity was determined by means of Ki-67 immunohistologic staining on primary tumors (55 patients) or at the relapse site (21 patients), and was classified as low ( 25% of stained cells) or high (> 25% of stained cells). The usual WHO response criteria were used. The median duration of follow-up was 18 months (range 3–58).Forty-seven patients (62%) had tumors with low, and 29 (38%) had tumors with a high rate of proliferative activity. The two groups were well balanced in terms of important variables such as disease-free survival, performance status, age, menopausal status, and the type of first-line chemotherapy (anthracycline-based regimens versus cyclophosphamide-methotrexate-5-fluorouracil). The estrogen receptor (ER) content, measured by means of immunohistochemical assay, was markedly different in the two groups, with 27/47 tumors with low proliferative activity (57%) and 6/29 with high-proliferative activity (21%) being ER positive ( 45% of stained cells) (p = 0.003). Moreover, a significant difference in the metastatic pattern was also evident, with a higher incidence of bone and a lower incidence of soft tissue metastases in the group of patients with tumors with low proliferative activity (p = 0.004). Overall, 10/47 responses (21%: PR = 7, and CR = 3) were observed in the group with a low rate of proliferative activity, versus 14/29 (48%: PR = 9, and CR = 5) in the group with highly proliferative tumors, the difference being statistically significant (p = 0.03). When a multivariate analy-sis was performed, the only factor that retained independent prognostic significance was the predominant site of disease, particularly soft tissues (p = 0.003). Despite the difference in response rate, when survival analysis was performed according to the Kaplan-Meier method, no significant difference was observed in the two groups, but when the analysis was limited to responsive patients, the median survival observed in those with a low and those with a high rate of proliferation was 35 and 19 months respectively (p = 0.02). The same results were obtained when multivariate survival analysis was carried out using Cox's regression model. These data suggest that there is a link between tumor proliferative activity and response to chemotherapy in advanced breast cancer, and may indicate the need to use more intensive treatments in selected patients with highly proliferative tumors.Presented in part at the Annual Meeting of the American Society of Clinical Oncology, May 14–17, 1994, Dallas, TX, USA 相似文献
6.
Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis 总被引:5,自引:0,他引:5
Annamaria Molino Giuseppe Pelosi Monica Turazza Loris Sperotto Andrea Bonetti Rolando Nortilli Giovanni Fattovich Cristoforo Alaimo Quirino Piubello Flavia Pavanel Rocco Micciolo Gian Luigi Cetto 《Breast cancer research and treatment》1997,42(1):23-30
Background: The presence in bone marrow of cells which react with monoclonal antibodies against tumor-associated antigens has been proposed over the last few years as a new prognostic factor in breast cancer patients. Patients and methods: Bone marrow aspirates were obtained from 109 stage I and II breast cancer patients during or 2–4 weeks after primary surgery. The samples were processed for leukocyte separation on a Ficoll-Hypaque gradient and then used to prepare cytospin slides for immunocytochemical analysis. The slides were stained with a pool of monoclonal antibodies (MoAbs) which recognize tumor associated antigens, using the alkaline phosphatase anti-alkaline phosphatase method. The median follow-up was 36 months (range 15–62); 22 patients relapsed and 7 died. Results: Thirty-four of the 109 patients (31.1%) had MoAb positive bone marrow cells. The bone marrow was positive in 28/74 (37.9%) patients who had the aspirate taken during surgery and in 6/35 (17.1%) who had it taken after surgery (p = 0.055). No association was found between bone marrow positivity and tumour size, nodal status, menopausal status, estrogen receptor positivity or the proliferative index. No association was found between bone marrow and prognosis: the log-rank test was 0.291 (p > 0.5) for OS and 0.023 for DFS; the hazard ratio (positive vs negative) was 1.51 for OS (95% CI: 0.33–6.86) and 0.93 for DFS (95% CI: 0.35–2.45). Conclusions: In our series, bone marrow positivity did not correlate with prognostic parameters or prognosis. Of interest is the relative excess of positivity when the bone marrow was obtained during surgery. 相似文献
7.
8.
Isabel G. Quirino Jose Silverio S. Diniz Maria Candida F. Bouzada Alamanda K. Pereira Thais J. Lopes Gabriela M. Paix?o Natalia N. Barros Luisa C. Figueiredo Antonio Carlos V. Cabral Ana Cristina Sim?es e Silva Eduardo A. Oliveira 《Clinical journal of the American Society of Nephrology》2012,7(3):444-451
9.
Joo V Nani Caroline Dal Mas Camila M Yonamine Vanessa K Ota Cristiano Noto Sintia I Belangero Jair J Mari Rodrigo Bressan Quirino Cordeiro Ary Gadelha Mirian A F Hayashi 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(11):721
BackgroundOur previous studies showed increased angiotensin I-converting enzyme (ACE) activity in chronic schizophrenia patients compared with healthy control (HC) volunteers, and the relevance of combining ACE genotype and activity for predicting schizophrenia was suggested.MethodsACE activity was measured in plasma of ACE insertion/deletion (I/D) genotyped HC volunteers (n = 53) and antipsychotic-naïve first-episode psychosis (FEP) patients (n = 45) assessed at baseline (FEB-B) and also after 2 months (FEP-2M) of treatment with the atypical antipsychotic risperidone.ResultsACE activity measurements showed significant differences among HC, FEP-B, and FEP-2M groups (F = 5.356, df = 2, P = .005) as well as between HC and FEP-2M (post-hoc Tukey’s multiple comparisons test, P = .004). No correlation was observed for ACE activity increases and symptom severity reductions in FEP as assessed by total Positive and Negative Syndrome Scale (r = −0.131, P = .434). FEP subgrouped by ACE I/D genotype showed significant ACE activity increases, mainly in the DD genotype subgroup. No correlation between ACE activity and age was observed in FEP or HC groups separately (r = 0.210, P = .392), but ACE activity level differences observed between these groups were influenced by age.ConclusionsThe importance of measuring the ACE activity in blood plasma, associated with ACE I/D genotyping to support the follow-up of FEP patients, did not show correlation with general symptom amelioration in the present study. However, new insights into the influence of age and I/D genotype for ACE activity changes in FEP individuals upon treatment was demonstrated. 相似文献
10.